SCHEMBL15210385

SCHEMBL15210385

COc1cc(-c2cc3nccc(-c4ccnc(O)c4)c3o2)cc(OC)c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4C Q08493 3/20 0.46
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 1/20 0.43
CALCRL Q16602 1/20 0.43
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40
CYP1A1 P04798 3/20 0.40
CYP1B1 Q16678 3/20 0.40
CYP1A2 P05177 1/20 0.40
PABPC1 P11940 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
SYK P43405 1/20 0.40
BRD4 O60885 4/20 0.39
ALOX5 P09917 2/20 0.39
PTGES O14684 1/20 0.39
FYN P06241 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723093 0.89 PDE4C (0.55) PDE4CALDH1A1CYP3A4CALCRLJAK2
SCHEMBL15210592 0.87 PDE4C (0.45) PDE4CALDH1A1CYP3A4CALCRLJAK2
SCHEMBL723624 0.87 PDE4C (0.47) PDE4CALDH1A1CYP3A4CALCRLJAK2
SCHEMBL723597 0.86 FYN (0.54) PDE4CALDH1A1CYP3A4CALCRLJAK2
SCHEMBL722839 0.84 PDE4C (0.51) PDE4CALDH1A1JAK2JAK1TYK2
SCHEMBL722596 0.83 PDE4C (0.50) PDE4CALDH1A1CYP3A4CALCRLJAK2
SCHEMBL16638610 0.83 PDE4C (0.47) PDE4CALDH1A1CYP3A4JAK2JAK1
SCHEMBL723790 0.83 PDE4C (0.47) PDE4CALDH1A1CYP3A4CALCRLJAK2
SCHEMBL723398 0.83 CALCRL (0.50) PDE4CALDH1A1CYP3A4CALCRLCYP1A1
SCHEMBL725087 0.83 FYN (0.53) PDE4CALDH1A1CYP3A4JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP claimed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US claimed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP claimed
CN-104114558-A Furopyridine derivatives MERCK PATENT GMBH 2014-10-22 CN claimed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO claimed
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP disclosed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US disclosed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP disclosed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038527-A1 FUROPYRIDINE DERIVATIVES SYK, LYN, BTK PDE4C 3343/4885ALDH1A1 2320/4885CYP3A4 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.